Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 9/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.33 |
| ▸ | FAP | Q12884 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6422872 | 1.00 | LMNA (0.36) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL2247974 | 0.84 | HSD17B10 (0.35) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL20914538 | 0.84 | DPP4 (0.34) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL2220706 | 0.81 | RAB9A (0.38) | LMNAHSD17B10CYP2C19DPP4DPP8 | |
| SCHEMBL20986580 | 0.80 | LMNA (0.35) | LMNAHSD17B10CYP2C19DPP4DPP8 | |
| SCHEMBL21356962 | 0.79 | LMNA (0.40) | LMNAHSD17B10CYP2C19DPP4DPP8 | |
| SCHEMBL5002190 | 0.77 | DPP4 (0.40) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL2430899 | 0.77 | DPP4 (0.40) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL4390283 | 0.77 | HSD17B10 (0.38) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL1920132 | 0.77 | DPP4 (0.40) | LMNAHSD17B10CYP2C19RIPK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-03-30 | — | — | US | disclosed |
| US-20200317673-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-10-08 | — | — | US | disclosed |
| US-20190152992-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ORION CORPORATION (FI) | 2019-05-23 | — | — | US | disclosed |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317673-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | MAP3K5, MAP3K2, MAPKAPK5 | LMNA 4349/4885HSD17B10 2663/4885CYP2C19 2686/4885 |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | LMNA 3485/4885HSD17B10 2129/4885CYP2C19 1061/4885 |
| US-20190152992-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | TBXA2R, ADRA2C, ADRB2 | LMNA 2674/4885HSD17B10 1797/4885CYP2C19 167/4885 |
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | MAP3K5, MAP3K2, MAPKAPK5 | LMNA 4349/4885HSD17B10 2663/4885CYP2C19 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.